Developments in purification methods for obtaining and evaluation of collagen derived endogenous angioinhibitors.
Collagen constitutes one of the vital components of the basement membrane scaffolds. Non-collagenous domains (NC1) derived from collagens exhibit potent anti-angiogenic properties, thus attaining significance in regulation of angiogenesis promoted diseases. Individual NC1 domains essential for anti-angiogenic evaluations are generally obtained through purification of individual non-collagenous domains, which have undergone steady developments for enhancing the yields, purpose of biological evaluations and solubility based on the nature of different NC1 domains. This review focuses on the method developments in obtaining biologically active NC1 domains and for specific evaluations in different scenarios.
The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Venugopal
V
Gunda
Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, 78363, USA.
Raj K
RK
Verma
Department of Genetics, Osmania University, Hyderabad, AP 500007, India.
Smita C
SC
Pawar
Cell Signaling Laboratory, Center for Cancer and Metabolism, Bioscience Division, SRI International, Menlo Park, CA 94025, USA. Electronic address: sudhakar.yakkanti@sri.com.
Yakkanti A
YA
Sudhakar
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics; D001485:Basement Membrane / Q000737:chemistry / Q000378:metabolism*; D024141:Collagen Type IV / Q000737:chemistry / Q000235:genetics / Q000302:isolation & purification*; D005109:Extracellular Matrix / Q000737:chemistry / Q000235:genetics; D005786:Gene Expression Regulation; D006801:Humans; D017434:Protein Structure, Tertiary
D020533:Angiogenesis Inhibitors; D024141:Collagen Type IV
Anti-angiogenesis; Different expression systems; Different purification methods; Extra cellular matrix (ECM); Non-collagenous domains (NC1); Type IV collagen